Navigation Links
Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
Date:12/8/2008

onal monoclonal antibodies.

About Micromet, Inc.

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company with offices in Bethesda, Maryland and Munich, Germany. The Company is developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company uses its proprietary BiTE(R) antibody platform to create a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease-related cells. Four of the Company's antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. Micromet is developing blinatumomab in collaboration with MedImmune, a subsidiary of AstraZeneca plc. Micromet's second BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights to MT110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a conventional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet has licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclini
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
5. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
6. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
7. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
8. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
9. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
10. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
11. Promising Data ATIR Studies Presented by NIH Investigators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... licensed to biotechnology firms has revealed early bottlenecks ... roadblocks, the researchers suggest that better communication of ... lead to faster commercialization down the road. , ... in university laboratories and licensed to biotechnology firms. ... have a high failure rate. But a new ...
(Date:8/20/2014)... American Indians largely were wiped out by diseases such ... to the New World by European explorers., One report ... in the Americas shortly before Europeans arrived, and roughly ... But new research led by anthropological geneticists Anne Stone ... University of Tubingen in Germany indicates the diagnosis of ...
(Date:8/20/2014)... the first time, chemists have succeeded in measuring vibrational ... resolution. The study reveals how vibration of a single ... , The study was performed at the University ... the University of Jyvskyl works as a visiting fellow ... the study. The second team was lead by Professor ...
(Date:8/20/2014)... Fla. , Aug. 20, 2014 ... will host a conference call to provide an ... 2014Time:4:30 p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. ... 9126599 Live web cast: www.neurotropebioscience.com , under "Investor ... hours after completion through September 2, 2014 at ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3Seeing a molecule breathe 2Neurotrope To Host Conference Call 2
... season on CEOs lately but when luminaries like management god ... something real and serious is taking place. Heres what Herr ... January 12, 2004 issue of Fortune Magazine, the compensation inflation ... of the management team. In an executive program I have ...
... Wis. The recent onslaught of e-mail viruses, overabundant ... for computer user protection. In light of this, ... Wisconsin companies, recently began offering new computer security technologies ... spam cost U.S. corporations $8.9 billion dollars in 2002 ...
... DEMO 2004 reaches its final week, I promised I'd share ... not just at DEMO, but in the week ahead. , ... it feels a lot like the enterprise market some 20 ... departments in the early 80s) is acutely focused on the ...
Cached Biology Technology:The CEO Crisis 2Wisconsin Telcos Offer New Internet Security Solutions 2The Enterprise and the Individual 2The Enterprise and the Individual 3
(Date:8/20/2014)... of Tennessee, Knoxville, research finds life can persist in ... was part of a team that examined waters and ... ice sheet and found the extreme environment supports microbial ... Jill Mikucki and her colleagues has implications for life ... the solar system. The findings are published in the ...
(Date:8/20/2014)... Issue Serious allergic reactions to food often ... some children.    What you should know ... and this number may be increasing, especially among children. Up ... food allergies.  The symptoms of allergic reactions ... difficulties and loss of consciousness. Symptoms can also develop at ...
(Date:8/20/2014)... Scientists from the University of Tbingen, Arizona State University, ... and Public Health Institute (Swiss TPH) isolated Mycobacterium ... at least 1000 years old. The pathogen is a ... only occasionally causes disease in humans today. These researchers ... the Peruvian coast. "The link to sea lions was ...
Breaking Biology News(10 mins):University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3
... and going to work is hard enough every day. But ... of your job down the smallest detail and the ... of credentials might mean starting from scratch. These are the ... make U.S. homes more energy efficient. A recent collaboration ...
... called ADAP (adhesion and degranulation-promoting adaptor protein) is able ... new University of Cambridge research reveals. The researchers, who ... discovery will lead to new ways of combatting HIV. ... who led the research, said: "One exciting aspect about ...
... Oct. 1, 2013  Pfenex Inc. today announced that the ... Biomedical Advanced Research and Development Authority (BARDA), has modified ... with the existing Pfenex contractual relationship begun in July, ... funding to support the development of a next generation ...
Cached Biology News:Weatherization work guidelines launched 2Weatherization work guidelines launched 3Weatherization work guidelines launched 4Weatherization work guidelines launched 5Weatherization work guidelines launched 6New target to fight HIV infection identified 2Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine 2
Goat polyclonal to STMN2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: AKTAMAYKEK, corresponding to C terminal amino acids 2-11 of STMN2. Entrez Gene ID: 11075 Swi...
Mouse monoclonal antibody to PAEP - progestagen-associated endometrial protein (placental protein 14, pregnancy-associated endometrial alpha-2-globulin, alpha uterine protein)...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Volume adapter mounts on top of the 96 well FiltrEX filter plate and allows larger volumes (1mL) to be applied to each well in a filter plate. Adapters are nonsterile....
Biology Products: